Azurity Pharmaceuticals Acquires Slayback Pharma
September 27, 2023
Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.
- Targets
- Slayback Pharma LLC
- Sellers
- KKR, Everstone Capital
- Platforms
- Azurity Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.